Other clinical trial failures

Unknown Borderline Personality Disorder trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.

Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.

funding was pulled

Phase IV Post-traumatic Stress Disorder trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Unable to meet enrollment goals

Phase IV Sedation trial by Nanfang Hospital, Southern Medical University. Stop reason: OPERATIONAL.

The trial was terminated early because additional sites did not recruit as planned, making the multicenter sample size infeasible. Enrollment ended after 117 participants were randomized at Nanfang Hospital, unrelated to safety, efficacy, or outcomes

Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.

Funding was pulled

Phase III Solitary Osseous Plasmacytoma trial by Alliance for Clinical Trials in Oncology. Stop reason: OPERATIONAL.

DSMB recommendation due to slow accrual

Phase III Hyperphagia trial by Aardvark Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Due to operational and regulatory considerations.

Early Phase I Opioid Use Disorder trial by Jacques E. Chelly. Stop reason: OPERATIONAL.

Study did not receive funding.

Phase III Hyperphagia trial by Aardvark Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Due to operational and regulatory considerations.

Phase I Leukodystrophy, Globoid Cell trial by Gemma Biotherapeutics. Stop reason: OPERATIONAL.

The study was stopped due to changes in the company strategy.

Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.

The trial has been temporarily suspended due to administrative issues

Phase IV Appendicitis trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Not feasible to complete trial due to low enrollment rate. Enrollment terminated and inadequately powered to achieve statistical significance on primary and secondary study outcomes.

Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.

The trial has been temporarily suspended due to administrative issues

Phase IV Familial Mediterranean Fever (FMF ) trial by Swedish Orphan Biovitrum. Stop reason: OPERATIONAL.

Business decision.

Phase III Degenerative Disc Disease trial by Angitia Biopharmaceuticals. Stop reason: OPERATIONAL.

Sponsor's strategic decision not related to safety concerns.

Phase II Hidradenitis Suppurativa trial by Insmed Incorporated. Stop reason: EFFICACY/FUTILITY.

Lack of Efficacy

Phase I Glioblastoma Multiforme of Brain trial by Chimeric Therapeutics. Stop reason: OTHER/UNKNOWN.

IND application withdrawn

Phase III Acquired Factor X Deficiency trial by Kedrion S.p.A.. Stop reason: OTHER/UNKNOWN.

Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis.

Phase I Healthy trial by Pfizer. Stop reason: OPERATIONAL.

The study was terminated for business reasons; there were no safety concerns.

Phase III Acute Major Bleeding trial by Octapharma. Stop reason: EFFICACY/FUTILITY.

Following Interim Analysis IDMEAC concluded:1-No safety concerns 2-Suspend enrolment: Futility based on treatment effect size at interim analysis. Enrollment was suspended on 22DEC25. Study was terminated FEB2026. Final analysis is planned in Q2 2026

Phase I Infertility trial by ART Fertility Clinics LLC. Stop reason: OPERATIONAL.

Difficulty of enrolling and recruiting patients

Phase III NSCLC trial by Spectrum Pharmaceuticals, Inc. Stop reason: OTHER/UNKNOWN.

The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.

Phase II Groin Injury trial by University Hospital, Bordeaux. Stop reason: OPERATIONAL.

target number of patient not reached and lost of financial supplies

Phase III Hereditary Hemorrhagic Telangiectasia trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.

target number of subject not reached

Phase III MPOX trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: EFFICACY/FUTILITY.

DSMB recommendation due to statistical futility

Phase II Pain, Postoperative trial by University of Florida. Stop reason: OPERATIONAL.

PI left institution.

Phase II Pain, Postoperative trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.

This study never got funded. It is not feasible to conduct this study without funding.

Phase III Hemodynamic Instability trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.

stop due to medication error with the placebo

Phase III Aortic Valve Stenosis trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.

target number of subjects not reached

Phase II FSGS trial by Apellis Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Study temporarily suspended due to company acquisition and ongoing strategic evaluation, with recruitment challenges including screening failures

Phase I Cerebral Adrenoleukodystrophy trial by Masonic Cancer Center, University of Minnesota. Stop reason: OTHER/UNKNOWN.

Awaiting supplies

Unknown Healthy trial by Centre Hospitalier Universitaire de Nīmes. Stop reason: OTHER/UNKNOWN.

20131209 Regulatory authorization is currently blocked at the ANSM.

Phase IV Pregnancy Preterm trial by University Hospitals Cleveland Medical Center. Stop reason: OPERATIONAL.

Low enrollment

Phase II Glycogen Storage Disease Type IB trial by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Stop reason: OPERATIONAL.

The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.

Phase IV Endometriosis trial by University of Louisville. Stop reason: OPERATIONAL.

Principal investigator did not have the necessary staffing resources to continue the study.

Phase III Azoospermia, Nonobstructive trial by Hospices Civils de Lyon. Stop reason: OPERATIONAL.

problems of feasibility

Phase II Hidradenitis Suppurativa (HS) trial by Boehringer Ingelheim. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

Phase IV Cesarean Section trial by Centre Hospitalier Universitaire de Nīmes. Stop reason: OTHER/UNKNOWN.

No inclusions.

Phase III Retinopathy of Prematurity trial by Jaeb Center for Health Research. Stop reason: OPERATIONAL.

Lack of feasibility to recruit.

Phase IV Otitis Media trial by Boston Children's Hospital. Stop reason: OPERATIONAL.

There was limited enrollment in the study.

Phase III Persistent Postoperative Pain trial by Benno Rehberg-Klug. Stop reason: OPERATIONAL.

insufficient funding and recruitment

Phase III Brain Injuries trial by University Hospital, Brest. Stop reason: EFFICACY/FUTILITY.

interim analysis - Results ongoing

Phase II Esophagitis trial by Pfizer. Stop reason: OPERATIONAL.

Pfizer has made an internal business decision to terminate the B1791094 study. This decision was not due to safety concerns or requests from any regulatory authorities.

Unknown Infertility trial by Centre Hospitalier Universitaire, Amiens. Stop reason: OPERATIONAL.

recruitement difficulties

Phase IV Aortic Stenosis, Non-rheumatic trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.

Difficulty of inclusion

Phase I Healthy Participants trial by UCB Biopharma SRL. Stop reason: OPERATIONAL.

sponsor decision

Phase II Alcohol Use Disorder trial by Hôpital le Vinatier. Stop reason: OTHER/UNKNOWN.

Péremption des unités de traitement prévue début juin 2026. Compte tenu des délais de traitement, aucune administration ne sera plus possible après le 1 février 2026. Ces facteurs ne permettent plus de garantir la poursuite des inclusions.

Phase II NSCLC trial by Spectrum Pharmaceuticals, Inc. Stop reason: OPERATIONAL.

Strategic business decision (unrelated to safety)

Phase II Peripheral Arterial Disease trial by Celularity Incorporated. Stop reason: OPERATIONAL.

The study was terminated early due to a business decision.

Phase I Glioblastoma Multiforme trial by Genenta Science. Stop reason: OTHER/UNKNOWN.

LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.

Unknown Cleft Palate trial by Centre Hospitalier Universitaire, Amiens. Stop reason: OPERATIONAL.

no participants enrolled

Unknown Complex Regional Pain Syndromes trial by McMaster University. Stop reason: OPERATIONAL.

Unable to recruit patients

Phase II Alopecia Areata trial by Sanofi. Stop reason: OPERATIONAL.

Sponsor decision; the decision is not related to any safety concern

Phase II Autistic Disorder trial by University Hospital, Limoges. Stop reason: OPERATIONAL.

the recently feasibility study shows that the number of patients is insufficient in the centers

Phase III Sleep Apnea trial by University Hospital, Limoges. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

Phase III Dravet Syndrome (DS) trial by Takeda. Stop reason: OTHER/UNKNOWN.

Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study

Phase I Periorbital Burns trial by Virginia Commonwealth University. Stop reason: OTHER/UNKNOWN.

Inventory not available

Phase II Alcohol Drinking trial by Yale University. Stop reason: OPERATIONAL.

On hold until new funding acquired.

Phase III Primary Biliary Cholangitis trial by Intercept Pharmaceuticals. Stop reason: OPERATIONAL.

Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.

Phase IV Recovery Following Cholecystectomy trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.

The study was halted due to the worldwide COVID-19 pandemic and the cancellation of all elective cases.

Phase I Astrocytoma, Grade IV trial by Celularity Incorporated. Stop reason: OPERATIONAL.

No participants were enrolled. Study was withdrawn prior to treatment initiation.

Phase I Sleep Disorders trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Lack of funding

Phase II Analgesia trial by Arthritis Innovation Corporation. Stop reason: OTHER/UNKNOWN.

Study superseded by alternative Phase 3 trial

Phase I Acute Myeloid Leukaemia trial by Sanofi. Stop reason: OPERATIONAL.

Sponsor's decision

Phase III Hamstring Contractures trial by GCS Ramsay Santé pour l'Enseignement et la Recherche. Stop reason: OPERATIONAL.

The site had difficulties to recruit. Some associated investigators can not be involved in the study anymore and others centers contacted don't have enough ressources to conduct the study. Premature end of inclusions on 07/10/2025 \& LPLV on11/27/2025

Phase IV Metrorrhagia trial by University of Chicago. Stop reason: OTHER/UNKNOWN.

Data not collected and analyzed; withdrawn due to lack of bandwidth.

Phase III Ebola Vaccine trial by Universitätsklinikum Hamburg-Eppendorf. Stop reason: OPERATIONAL.

Public funding was withdrawn before the start of the clinical trial.

Phase II Anticholinergic Toxicity trial by Washington University School of Medicine. Stop reason: OTHER/UNKNOWN.

Physostigmine (standard of care treatment under this protocol) became unavailable at the study site June 1st 2026, requiring suspension of the study.

Unknown Heat Stroke trial by Second Affiliated Hospital, School of Medicine, Zhejiang University. Stop reason: OTHER/UNKNOWN.

Terminated due to protocol amendment: intervention window changed from entire ED stay to first 2h after ED admission. Revised protocol will be registered separately.

Phase II Hyperalgesia trial by University of California, Irvine. Stop reason: OPERATIONAL.

Study terminated early due to low enrollment. Only 8 participants enrolled out of the target 105.

Phase IV Arthroplasty, Replacement, Knee trial by McMaster University. Stop reason: OPERATIONAL.

Unable to secure funding.

Phase II Noise Induced Hearing Loss trial by Sound Pharmaceuticals, Incorporated. Stop reason: OTHER/UNKNOWN.

Study did not start

Phase II Progressive Glioblastoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Scheduled Interim Monitoring

Phase I Glucocorticoid-Refractory aGVHD trial by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Stop reason: OPERATIONAL.

This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Phase I Healthy Adult trial by Dong-A ST Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Discontinuation of Clinical Trial

Phase II Opioid-Use Disorder trial by National Institute on Drug Abuse (NIDA). Stop reason: OTHER/UNKNOWN.

Drug availability

Phase II Pharmacokinetic Study trial by Boston University. Stop reason: OTHER/UNKNOWN.

The investigator moved to another institution; only preliminary data from pharmacokinetic studies were collected at Boston University School of Medicine/Boston Medical Center.

Phase I Critical Asymptomatic Carotid Artery Disease trial by University of Alabama at Birmingham. Stop reason: OPERATIONAL.

Recruitment issues

Phase III Chronic Intracranial Subdural Hematoma trial by University Hospital, Montpellier. Stop reason: EFFICACY/FUTILITY.

successfull Interim Analysis

Phase II Glioblastoma trial by photonamic GmbH & Co. KG. Stop reason: OPERATIONAL.

Low recruitment activities of clinical trial sites.

Phase IV Otolaryngologic Surgery trial by University of Minnesota. Stop reason: OTHER/UNKNOWN.

The current PI is leaving the study. Study team is awaiting FDA PI change approval.

Phase II Hemangioma, Capillary trial by University Hospital, Bordeaux. Stop reason: OPERATIONAL.

Study halted prematurely due to some difficulties in recruitment of patients

Unknown Thoracic Injuries trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.

changes in patient care that move them further away from the inclusion criteria

Phase I Vestibular Schwannoma trial by Northwell Health. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

Phase I Glioblastoma Multiforme trial by Northwell Health. Stop reason: OPERATIONAL.

PI left previous institution study will reopen at new institution.

Phase I Squamous NSCLC trial by CureVac. Stop reason: OPERATIONAL.

In accordance with 21 CFR 312.38, CureVac is herewith withdrawing IND No. 031346 for CV09070101 (referred to as CVHNLC) for the indication of squamous Non-Small-Cell Lung Cancer (sqNSCLC), following the strategic decision to not pursue the CVHNL

Phase IV Peripheral Arterial Disease trial by Mayo Clinic. Stop reason: OPERATIONAL.

Lack of funds

Phase III Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD) trial by Applied Therapeutics, Inc.. Stop reason: OPERATIONAL.

The study was withdrawn prior to enrollment as the sponsor decided not to proceed with study initiation.

Phase II Hidradenitis Suppurativa trial by Beth Israel Deaconess Medical Center. Stop reason: OPERATIONAL.

Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding

Phase II Shift-Work Sleep Disorder trial by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Stop reason: OPERATIONAL.

In agreement with all parties, the project was closed on March 31 due to recruitment challenges.

Unknown Connective Tissue Diseases trial by Guangzhou Bio-gene Technology Co., Ltd. Stop reason: OTHER/UNKNOWN.

Due to corporate strategic adjustment.

Early Phase I Hair Loss trial by Guangzhou Bio-gene Technology Co., Ltd. Stop reason: OTHER/UNKNOWN.

Per updated regulatory requirements, the site is ineligible to proceed. The clinical institution office has terminated the project.

Phase I Chronic Pain trial by Lohocla Research Corporation. Stop reason: OPERATIONAL.

Terminated by sponsor due to low drug bioavailability; no safety concerns were noted.

Unknown Rapid Sequence Induction trial by Centre Hospitalier Sud Francilien. Stop reason: OTHER/UNKNOWN.

rate of inclusion too low

Phase IV Infant Mortality trial by Bandim Health Project. Stop reason: OTHER/UNKNOWN.

Due to fewer than expected children enrolled and lower than expected overall mortality rate.

Phase III Subarachnoid Hemorrhage, Aneurysmal trial by Centre Hospitalier Universitaire de Nice. Stop reason: OTHER/UNKNOWN.

The treatments are no longer available.

Phase II Adult Growth Hormone Deficiency (AGHD) trial by Changchun GeneScience Pharmaceutical Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Adjustment of sponsor's product development strategy.

Phase II Stroke trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.

Negativity of the first results of in vivo binding of 18F-PBR06

Phase II Arteriovenous Malformations trial by University Health Network, Toronto. Stop reason: OPERATIONAL.

No patients enrolled

Phase I Hearing Loss, Sensorineural trial by Seoul National University Hospital. Stop reason: OPERATIONAL.

This study was withdrawn before enrollment due to challenges in participant recruitment. A revised study protocol will be initiated under a new research project.